LGVN
NASDAQ
US
Longeveron Inc. - Class A Common stock
$1.07
▼ $-0.05
(-4.46%)
Vol 1.2M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$10.8M
ROE
-138.4%
Margin
-1485.1%
D/E
0.00
Beta
0.18
52W
$1–$2
Wall Street Consensus
8 analysts · Apr 20262
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
PSTV
Plus Therapeutics Inc
$70.4M
BOLD
Boundless Bio Inc
$26.9M
CYCN
Cyclerion Therapeutics Inc
$5.0M
NEUP
Neuphoria Therapeutics Inc
$20.9M
SKYE
Skye Bioscience Inc
$24.0M
VTGN
Vistagen Therapeutics Inc
$26.1M
SNTI
Senti Biosciences Inc
$27.3M
MRKR
Marker Therapeutics Inc
$24.8M
CRIS
Curis Inc
$12.8M
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.42 | $-0.23 | +$0.19 |
| Sep 2025 | $-0.26 | $-0.39 | $-0.13 |
| Jun 2025 | $-0.36 | $-0.33 | +$0.03 |
| Mar 2025 | $-0.33 | $-0.34 | $-0.01 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -95.9% | -85.1% | -95.9% | -95.9% | -138.4% | -138.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -1591.1% | -760.6% | -894.3% | -894.3% | -1485.1% | -1485.1% |
| Gross Margin | 46.2% | 82.3% | 78.8% | 78.8% | 74.9% | 74.9% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.43 | 5.61 | 3.43 | 3.43 | 2.09 | 2.09 |
Key Ratios
ROA (TTM)
-108.5%
P/S (TTM)
7.51
P/B
1.2
EPS (TTM)
$-1.34
CF/Share
$-0.89
Rev Growth 3Y
+22.4%
52W High
$2.24
52W Low
$0.52
$0.52
52-Week Range
$2.24
How does LGVN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
LGVN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.5
▼
42%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.2
▼
52%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
LGVN profitability vs Biotechnology peers
ROE
-138.4%
▼
106%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-1485.1%
▼
418%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
74.9%
▼
5%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-108.5%
▼
132%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
LGVN financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
2.1
▼
53%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.2
▼
82%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
LGVN fundamentals radar
LGVN
Peer median
Industry
LGVN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
LGVN vs peers: key metrics
Latest News
No related news yet